Sekeres MA - Search Results

1

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Sekeres MA, et al. Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22. Blood. 2012. PMID: 22915641 Free PMC article. Clinical Trial.

2

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.

Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM; Cancer and Leukemia Group B. Sekeres MA, et al. Blood. 2004 Jun 1;103(11):4036-42. doi: 10.1182/blood-2003-09-3118. Epub 2004 Feb 19. Blood. 2004. PMID: 14976037 Free article.

3

Arsenic trioxide as a treatment for myelodysplastic syndrome.

Sekeres MA. Sekeres MA. Curr Hematol Rep. 2005 Jan;4(1):59-63. Curr Hematol Rep. 2005. PMID: 15610661 Review.

4

Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?

Sekeres MA, List A. Sekeres MA, et al. Curr Hematol Rep. 2005 May;4(3):182-5. Curr Hematol Rep. 2005. PMID: 15865869 Review.

5

Alternative treatments for myelodysplastic syndromes.

Sekeres M, List A. Sekeres M, et al. Semin Hematol. 2005 Jul;42(3 Suppl 2):S32-7. doi: 10.1053/j.seminhematol.2005.05.008. Semin Hematol. 2005. PMID: 16015503 Review.

6

The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.

Abou-Jawde RM, Sobecks R, Pohlman B, Rybicki L, Advani A, Sekeres M, Kalaycio M. Abou-Jawde RM, et al. Leuk Lymphoma. 2006 Apr;47(4):689-95. doi: 10.1080/10428190500353554. Leuk Lymphoma. 2006. PMID: 16690528

7

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Szpurka H, et al. Among authors: sekeres ma. Blood. 2006 Oct 1;108(7):2173-81. doi: 10.1182/blood-2006-02-005751. Epub 2006 Jun 1. Blood. 2006. PMID: 16741247 Free PMC article.

8

Immunomodulation in myelodysplastic syndromes.

Sekeres MA, List A. Sekeres MA, et al. Best Pract Res Clin Haematol. 2006;19(4):757-67. doi: 10.1016/j.beha.2006.06.001. Best Pract Res Clin Haematol. 2006. PMID: 16997181 Review.

9

Managing patients with low-risk MDS.

Sekeres M, Cosgrove D, Falco A. Sekeres M, et al. Clin Adv Hematol Oncol. 2006 Jul;4(7 Suppl 16):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2006. PMID: 17139240 Review.

10

High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.

O'Keefe CL, Tiu R, Gondek LP, Powers J, Theil KS, Kalaycio M, Lichtin A, Sekeres MA, Maciejewski JP. O'Keefe CL, et al. Among authors: sekeres ma. Exp Hematol. 2007 Feb;35(2):240-51. doi: 10.1016/j.exphem.2006.09.016. Exp Hematol. 2007. PMID: 17258073 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters